Free tool
FAERS Monitor: Zenpep
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022210 or its brand name (Zenpep, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.
Reports
6,026
Serious
3,528
59% of reports
Hospitalization
2,308
Death reported
408
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea500
- infective pulmonary exacerbation of cystic fibrosis451
- hospitalisation329
- death296
- cystic fibrosis287
- nausea279
- headache255
- fatigue238
- pneumonia233
- weight decreased222
- drug ineffective209
- abdominal pain205
- dyspnoea201
- constipation200
- cough198
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 10 |
| 2011 | 10 |
| 2012 | 25 |
| 2013 | 59 |
| 2014 | 100 |
| 2015 | 217 |
| 2016 | 333 |
| 2017 | 337 |
| 2018 | 541 |
| 2019 | 944 |
| 2020 | 778 |
| 2021 | 318 |
| 2022 | 370 |
| 2023 | 562 |
| 2024 | 544 |
| 2025 | 518 |
| 2026 | 360 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 451 | 315.2 | 287.3 | 129,326 |
| cystic fibrosisSignal | 287 | 190.8 | 169.9 | 51,204 |
| hospitalisationSignal | 329 | 7.5 | 6.7 | 1,852 |
| constipationSignal | 200 | 3.2 | 2.8 | 304 |
| abdominal painSignal | 205 | 3.1 | 2.7 | 288 |
| weight decreasedSignal | 222 | 2.8 | 2.4 | 254 |
| diarrhoeaSignal | 500 | 2.7 | 2.5 | 552 |
| pneumoniaSignal | 233 | 2.5 | 2.2 | 214 |
| coughSignal | 198 | 2.5 | 2.1 | 173 |
| headache | 255 | 1.4 | 1.3 | 32 |
| dyspnoea | 201 | 1.2 | 1.1 | 9 |
| nausea | 279 | 1.2 | 1.1 | 12 |
| death | 296 | 1.2 | 1.1 | 10 |
| fatigue | 238 | 1.1 | 0.9 | 1 |
| drug ineffective | 209 | 0.6 | 0.5 | 80 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.